|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, we observed decreased HLA-A, -B, and -C expression (<i>p</i> = 0.036, <i>p</i> = 0.026, and <i>p</i> = 0.030, respectively) as well as increased ratios of CTLA-4, PD-1, Tim-3, and LAG3 to CD8A expression (<i>p</i> = 0.0064, <i>p</i> = 0.017, <i>p</i> = 0.033 and <i>p</i> = 0.0136, respectively) in stage I-II tumors with high neoAg frequencies.
|
28920005 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After primary tumour removal, a course of three subcutaneous vaccinations with LLC lysate supplemented with BGs led to a significant increase in overall survival (80% after 84 days of follow‑up vs. 40% in untreated control mice), a significant increase in circulating CD8a+ T cells (16.57 vs. 12.6% in untreated control mice) and a significant decrease in metastasis foci area and incidence.
|
27878261 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Compared with other endometrial cancers, POLE mutants displayed an enhanced cytotoxic T-cell response, evidenced by increased numbers of CD8(+) tumor-infiltrating lymphocytes and CD8A expression, enrichment for a tumor-infiltrating T-cell gene signature, and strong upregulation of the T-cell cytotoxic differentiation and effector markers T-bet, Eomes, IFNG, PRF, and granzyme B.
|
25878334 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Attenuation of p32 expression reduced growth rate of glioma cells expressing Myc and impaired tumor formation in vivo.
|
25528767 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The bispecific antibodies simultaneously engaged the cognate antigens (murine T cell co-receptor CD3 and hen egg lysozyme) and selectively accumulated on murine tumors in vivo.
|
23032949 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because of these results and that no mutations were detected on the two genes in a previous study, we think that Leu1 and Leu2 can be excluded as tumor suppressor genes.
|
10516767 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that the Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.
|
9395242 |
1997 |
|
Bronchiectasis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Recurrent viral infection
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Recurrent bacterial infection
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Recurrent respiratory infections
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Absence of CD8-positive T cells
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
LyP-1 is a peptide that binds to the p32 receptor which is highly expressed not only on the lymphatic endothelium but also on the malignant cells; thus, making this peptide ligand a preferable candidate to mediate active targeting of lymphatics and cancer cells.
|
30660694 |
2019 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
<b>Materials and methods:</b> In the present study, we reanalyzed data from four public datasets (the Cancer Genome Atlas for investigation; and CIT, GSE5287, and GSE31684 for validation) to examine the prognostic significance of CD3D, CD4, CD8A, CD3D/CD4 and CD3D/CD8A in MIBC.
|
31114346 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
<b>Materials and methods:</b> In the present study, we reanalyzed data from four public datasets (the Cancer Genome Atlas for investigation; and CIT, GSE5287, and GSE31684 for validation) to examine the prognostic significance of CD3D, CD4, CD8A, CD3D/CD4 and CD3D/CD8A in MIBC.
|
31114346 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
LyP-1 is a peptide that binds to the p32 receptor which is highly expressed not only on the lymphatic endothelium but also on the malignant cells; thus, making this peptide ligand a preferable candidate to mediate active targeting of lymphatics and cancer cells.
|
30660694 |
2019 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
LyP-1-SPIONs are promising in treating cancer as they accumulated in the nucleus of MCF-7 cells which expressed p32 and almost stopped tumor growth by combined MIH and targeted therapy.
|
29165044 |
2018 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The Cancer Genome Atlas analysis confirmed that patients with a favorable immune and metabolic gene signature (high CD8A, high COX5B, low GLUT1) had improved short- and long-term survival.
|
29107073 |
2018 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Within the knowledge of the critical role of p32 receptor in cancer cell metabolism, this study can lead to further developments in anticancer therapy by targeting p32 with LyP-1 derivatives as active targeting moiety.
|
28427307 |
2018 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Therefore, an idea of blocking the checkpoint molecules to enhance the anti-tumor activities of the host immune system has been developed and applied to the cancer therapy after discovery of the inhibitory T cell co-receptor, cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and further enhanced on the identification of PD-1 and its ligands.
|
29991709 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Within the knowledge of the critical role of p32 receptor in cancer cell metabolism, this study can lead to further developments in anticancer therapy by targeting p32 with LyP-1 derivatives as active targeting moiety.
|
28427307 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
The Cancer Genome Atlas analysis confirmed that patients with a favorable immune and metabolic gene signature (high CD8A, high COX5B, low GLUT1) had improved short- and long-term survival.
|
29107073 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Therefore, an idea of blocking the checkpoint molecules to enhance the anti-tumor activities of the host immune system has been developed and applied to the cancer therapy after discovery of the inhibitory T cell co-receptor, cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and further enhanced on the identification of PD-1 and its ligands.
|
29991709 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
LyP-1-SPIONs are promising in treating cancer as they accumulated in the nucleus of MCF-7 cells which expressed p32 and almost stopped tumor growth by combined MIH and targeted therapy.
|
29165044 |
2018 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Identifying small molecule inhibitors of p32 overexpressed in cancer is a more rational therapeutic strategy.
|
29047383 |
2017 |